Solid Biosciences announces Phase 1b trial for SGT-501, a gene therapy for catecholaminergic polymorphic ventricular tachycardia, with FDA designations. Solid Biosciences Inc. has announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback